Fluid balance management with loop diuretics in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A case series

• DOI: 10.1016/j.hest.2023.10.003
• Publication Date: 2023-10-16T16:42:01Z
• Authors: Yosuke Akamatsu; Kohei Chida; Kenya Miyoshi; Daigo Kojima; Jun-Ichi Nomura; Kengo Setta; Takayuki Chiba; Takahiro Koji; Shunrou Fujiwara; Hiroshi Kashimura; Yoshitaka Kubo; Kuniaki Ogasawara
• Keywords: Neurophysiology and neuropsychology; 03 medical and health sciences; 0302 clinical medicine; Aneurysmal subarachnoid hemorrhage; QP351-495; Clazosentan; Symptomatic vasospasm

Pulmonary edema is a common complication in patients receiving clazonsentan. Here, we report our experience managing fluid balance with loop diuretics aneurysmal subarachnoid hemorrhage (aSAH) treated clazosentan. Patients aSAH who received prophylactic agents for vasospasm after aneurysm obliteration between June 2021 and April 2023 were enrolled. Fluid parameters asymptomatic symptomatic pulmonary incidence compared three periods: 1st period (fasudil therapy), 2nd (clazosentan therapy alone), 3rd diuretic therapy). intake urine volume during the periods considerably lesser than those period. Asymptomatic was that periods. However, incidences of rescue endovascular treatment comparable among groups. Although clinical outcomes at last follow-up groups, markedly higher Thus, proper management clazosentan would help effective prophylaxis.